Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy: A Pooled Analysis on Asian versus Non-Asian.

Published byDinah Price Modified over 5 years ago

Similar presentations

Presentation on theme: "Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy: A Pooled Analysis on Asian versus Non-Asian."— Presentation transcript:

1 Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy: A Pooled Analysis on Asian versus Non-Asian in Phase II and III Clinical Trials  Yoshikazu Hasegawa, MD, Tomoya Kawaguchi, MD, PhD, Akihito Kubo, MD, PhD, Masahiko Ando, MD, PhD, Junji Shiraishi, PhD, Shun-ichi Isa, MS, Taisuke Tsuji, MD, Kazuyuki Tsujino, MD, Sai-Hong I. Ou, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Minoru Takada, MD, PhD  Journal of Thoracic Oncology  Volume 6, Issue 11, Pages (November 2011) DOI: /JTO.0b013e b6 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1. Schematic diagram of sensitivity analysis.
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e b6) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2. Flow chart showing the progress of trials through the review. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e b6) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3. Comparison of grades 3 and 4 hematological toxicity between combined Asian and non-Asian trials. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e b6) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4. Comparison of grades 3 and 4 hematological toxicity between Asian and non-Asian trials; scatterplot. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e b6) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5. Sensitivity analysis: green dotted line represents the OR of 1. Red and yellow dotted lines represent probability with 95% confidence. Yellow dotted line is the highest probability. Red dotted line is the lowest probability. A difference is found when using the high figure in Figure 3. Because this is not representative of the entire group, it does not show a difference among all cases. If we use the lowest number, we reduce the margin of error to be more accurate. In this study, severe neutropenia and anemia were more frequently observed in Asians, excepting severe thrombocytopenia. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e b6) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

7 FIGURE 6. Survival and race: the comparison of overall survival time by using Student's t test. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e b6) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy: A Pooled Analysis on Asian versus Non-Asian."

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.

Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing.

Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing.
Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.

Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.
Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

Similar presentations

Ads by Google